SELLAS Life Sciences Group (SLS) Q2 2024 earnings summary

Executive summary

• The company is a late-stage biopharma focused on cancer therapeutics, with lead candidates GPS (immunotherapy) and SLS009 (CDK9 inhibitor).

• REGAL Phase 3 trial for GPS in AML completed enrollment; IDMC recommended continuation without modifications, with interim analysis expected Q4 2024.

• SLS009 Phase 2a trial in AML showed promising response rates, including ORR of 33%, 50%, and 100% in various cohorts, especially in ASXL1 mutation patients.

• Multiple regulatory designations granted for GPS and SLS009, including Orphan Drug, Fast Track, and Rare Pediatric Disease status in the US and EU.

• $21 million capital raise in August 2024, priced at a premium to market, strengthens financial position.

Financial highlights

• Net loss for Q2 2024 was $7.5 million ($0.13/share), down from $8.8 million ($0.31/share) in Q2 2023; six-month net loss was $17.0 million ($0.33/share), down from $19.9 million ($0.77/share) year-over-year.

• Operating expenses for Q2 2024 were $7.6 million, a decrease from $9.1 million in Q2 2023.

• Cash and cash equivalents as of June 30, 2024 were $9.1 million, with an additional $0.1 million in restricted cash; subsequent $21 million capital raise completed.

• No product sales revenue; licensing revenue from 3D Medicines Agreement remains contingent on milestones.

• R&D expenses for Q2 2024 were $5.2 million, down from $5.9 million in Q2 2023; G&A expenses for Q2 2024 were $2.4 million, down from $3.1 million in Q2 2023.

Outlook and guidance

• Interim analysis for Phase 3 REGAL study in AML projected for Q4 2024, with 60 events expected to trigger analysis.

• Topline data from ongoing SLS009 and GPS studies, and initial pediatric tumor data from NIH PIVOT program, expected in the second half of 2024.

• Additional financing will be required to support ongoing R&D and operations.

• Cash and proceeds from the August 2024 offering are not sufficient to fund operations for the next twelve months; substantial doubt exists about going concern status.